News Discovery of KT-474, a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases 9/26/23 Read more Safety and Efficacy of IRAK4 Degrater KT-474 (SAR444656) for Hidradenitis Suppurativa and Atopic Dermatitis 5/18/23 Read more Proteomics enabling TPD Drug Discovery 12/7/22 Read more The Phase 1 Healthy Volunteer Clinical Trial of KT-474 10/26/22 Read more Development and Performance of Pharmacodynamic Assays to Demonstrate Proof-of-Mechanism for IRAK4 Degraders in a Phase1 Study 10/26/22 Read more Utilizing degraders to Modulate B & T Cell Targets for Autoimmune Diseases 7/28/22 Read more Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications 6/7/22 Read more Discovery and targeted mass spectrometry-based proteomics: Enabling technologies advancing IRAK4 protein degrader along the drug discovery pipeline into the clinic 6/6/22 Read more Kinetics of IRAK4 Degradation and Impact on Functional Response in Circulating Immune Cells and Skin Cell Subsets 5/17/22 Read more Selective IRAK4 Degradation, Not Kinase Inhibition, Blocks TLR-activated NF-kB and p38 Signaling Leading to broad Cytokine Inhibition 5/3/22 Read more
